Table 2 Univariable and multivariable logistic regression analysis

RR^a

95% CI^b

P

Gender (Male, Female)

1.12

0.91–1.22

0.67

Age(<60, >60 years)

1.03

0.98–1.17

0.61

Intravesical instillation (immediate, maintenance)

0.98

0.89–1.78

0.27

Tumor stage (Ta, T1)

1.34

1.03–1.56

0.67

Tumor grade (G1 and G2, G3)

2.78

1.05–6.93

0.01

Concomitant CIS (No, Yes)

1.52

0.21–7.43

0.66

Tumor size (<3, >3 cm)

2.11

1.29–4.32

0.05

Multiplicity (Single, Multiple)

1.98

0.98–3.92

0.07

CLASP2 mRNA (low, high in tumor)

3.83

1.12–12.22

0.02

CLASP2 mRNA (low, high in urine)

2.71

1.09–7.77

< 0.01

E-cadherin mRNA (high, low in tumor)

2.97

1.17–9.82

0.04

E-cadherin mRNA (high, low in urine)

3.24

0.97–10.81

0.02

Vimentin mRNA (low, high in tumor)

1.24

0.78–2.87

0.32

Vimentin mRNA (low, high in urine)

1.19

0.26–4.98

0.09

RR

95% CI

P

Tumor stage (Ta, T1)

1.14

0.91–1.86

0.78

Tumor grade (G1 and G2, G3)

2.19

1.01–4.98

0.04

Tumor size (<3, >3 cm)

1.71

1.08–3.37

0.07

Intravesical instillation (immediate, maintenance)

1.12

0.79–1.45

0.52

Multiplicity (Single, Multiple)

2.32

1.18–4.22

0.18

CLASP2 mRNA (low, high in tumor)

2.76

1.02–10.11

< 0.01

CLASP2 mRNA (low, high in urine)

3.75

1.09–6.12

< 0.01

E-cadherin mRNA (high, low in tumor)

2.78

1.17–8.24

0.01

E-cadherin mRNA (high, low in urine)

3.34

1.12–7.45

0.01

Vimentin mRNA (low, high in tumor)

1.35

0.89–3.43

0.51

Vimentin mRNA (low, high in urine)

1.78

0.26–3.48

0.35